| 1 |
Yang S, Zhang Z, Wang Q. Emerging therapies for small cell lung cancer[J]. J Hematol Oncol, 2019，12(1): 47.
|
| 2 |
Montenegro GB, Farid S, Liu SV. Immunotherapy in lung cancer[J]. J Surg Oncol, 2021, 123(3): 718-729.
|
| 3 |
Horn L, Mansfield AS, Szcz sna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer[J]. N Engl J Med, 2018, 379(23): 2220-2229.
|
| 4 |
Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2019, 394(10212): 1929-1939.
|
| 5 |
Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase Ⅲ KEYNOTE-604 study[J]. J Clin Oncol, 2020, 38(21): 2369-2379.
|
| 6 |
Gadgeel SM, Pennell NA, Fidler MJ, et al. Phase Ⅱ study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC) [J]. J Thorac Oncol, 2018, 13(9): 1393-1399.
|
| 7 |
Owonikoko TK, Park K, Govindan R, et al. Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451[J]. J Clin Oncol, 2021, 39(12): 1349-1359.
|
| 8 |
van Meerbeeck Jan P, Fennell Dean A, De Ruysscher Dirk KM. small-cell lung cancer[J]. Lancet, 2011, 378(9804): 1741-1755.
|
| 9 |
Nobuyuki Horita, Masaki Yamamoto, Takashi Sato, et al. Topotecan for relapsed small-cell lung cancer: systematic review and meta-analysis of 1347 patients[J]. Sci Rep, 2015, 5: 15437.
|
| 10 |
Spigel DR, Vicente D, Ciuleanu TE, et al. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331(☆)[J]. Ann Oncol, 2021, 32(5): 631-641.
|
| 11 |
Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial[J]. Lancet Oncol, 2016, 17(7): 883-895.
|
| 12 |
Chung HC, Piha-Paul SA, Lopez-Martin J, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies[J]. J Thorac Oncol, 2020, 15(4): 618-627.
|
| 13 |
Yu H, Boyle TA, Zhou C, et al. PD-L1 expression in lung cancer[J]. J Thorac Oncol, 2016, 11(7): 964-975.
|
| 14 |
Ott PA, Elez E, Hiret S, et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study[J]. J Clin Oncol, 2017, 35(34): 3823-3829.
|
| 15 |
Chung HC, Ros W, Delord JP, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase Ⅱ KEYNOTE-158 study[J]. J Clin Oncol, 2019, 37(17): 1470-1478.
|
| 16 |
Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer[J]. Nature, 2013, 500(7463): 415-421.
|
| 17 |
Horn L, Dahlberg SE, Sandler AB, et al. Phase Ⅱ study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: eastern cooperative oncology group study E3501[J]. J Clin Oncol, 2009, 27(35): 6006-6011.
|
| 18 |
Ready NE, Dudek AZ, Pang HH, et al. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase Ⅱ study[J]. J Clin Oncol, 2011, 29(33): 4436-4441.
|
| 19 |
Tiseo M, Boni L, Ambrosio F, et al. Italian, multicenter, phase Ⅲ，randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer: the GOIRC-AIFA FARM6PMFJM trial[J]. J Clin Oncol, 2017, 35(12): 1281-1287.
|
| 20 |
Cheng Y, Wang Q, Li K, et al. 1738OOverall survival (OS) update in ALTER 1202: anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC)[J]. Annal Oncol, 2019，30(Supplement_5): DOI： 10.1093/annonc/mdz264.002 |
| 21 |
Han B, Zhang W, Zhang B, et al. P48.09 anlotinib plus etoposide and carboplatin as first-line treatment for extensive-stage small cell lung cancer: a single arm phase Ⅱ trial[J]. J Thorac Oncol, 2021, 16(3): S503.
|
| 22 |
Chabanon RM, Muirhead G, Krastev DB, et al. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer[J]. J Clin Invest, 2019, 129(3): 1211-1228.
|
| 23 |
Jiang Y, Dai H, Li Y, et al. PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer[J]. Int J Cancer, 2019, 144(5): 1092-1103.
|
| 24 |
Owen DH, Giffin MJ, Bailis JM, et al. DLL3: an emerging target in small cell lung cancer[J]. J Hematol Oncol, 2019, 12(1): 61.
|
| 25 |
Jiao S, Xia W, Yamaguchi H, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression[J]. Clin Cancer Res, 2017, 23(14): 3711-3720.
|
| 26 |
Sen T, Rodriguez BL, Chen L, et al. Targeting DNA damage response promotes antitumor immunity through STING-Mediated T-cell activation in small cell lung cancer[J]. Cancer Discov, 2019, 9(5): 646-661.
|
| 27 |
Dwight H Owen, Michael J Giffin, Julie M Bailis, et al. DLL3: an emerging target in small cell lung cancer[J]. J Hematol Oncol, 2019, 12(1): 61.
|
| 28 |
Megumi Furuta, Jun Sakakibara-Konishi, Hajime Kikuchi, et al. Analysis of DLL3 and ASCL1 in surgically resected small cell lung cancer (HOT1702)[J]. Oncologist, 2019, 24(11): e1172-e1179.
|
| 29 |
Rudin CM, Pietanza MC, Bauer TM, et al. Rovalpituzumabtesirine，a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study[J]. Lancet Oncol, 2017, 18(1): 42-51.
|
| 30 |
Morgensztern D, Besse B, Greillier L, et al. Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: results from the phase Ⅱ TRINITY study[J]. Clin Cancer Res, 2019, 25(23): 6958-6966.
|